We first tested the effects of RBM47 on cancer cell Wnt responsiveness by treating WT6 cells with recombinant Wnt3A and subsequently measuring the expression of AXIN2, a common TCF/β-catenin target gene and a general marker of Wnt activity (Lustig et al., 2002; Clevers and Nusse, 2012). The gene discussed is AXIN2; the disease is cancer.